How to Get Zepbound in Arkansas

What Is Zepbound and Why Does It Matter for Arkansas Patients?

Zepbound is Eli Lilly's brand-name tirzepatide, approved by the FDA in November 2023 specifically for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. It is the first and only dual GIP/GLP-1 receptor agonist approved for this indication. That dual mechanism separates it from semaglutide-based drugs, which act on GLP-1 alone.

Arkansas ranks among the top five states for adult obesity prevalence, with a rate exceeding 40% according to CDC adult obesity data. Access to effective pharmacotherapy here is not a luxury. In the SURMOUNT-1 trial (N=2,539), participants randomized to tirzepatide 15 mg achieved a mean body weight reduction of 22.5% at 72 weeks, compared to 3.1% with placebo. The 10 mg arm lost 21.4%, and the 5 mg arm lost 16.0%. These results represent the largest weight reductions seen in any Phase III obesity trial to date.

For Arkansas residents, three pathways exist: a visit with a local prescriber, a telehealth consultation with a licensed provider, or referral through a hospital-based obesity medicine program. Each route involves the same clinical criteria, but the logistics differ.

Who Can Prescribe Zepbound in Arkansas?

Any Arkansas-licensed clinician with prescriptive authority can write a Zepbound prescription. That means MDs, DOs, nurse practitioners (APRNs with full practice authority under Arkansas Act 536), and physician assistants operating under collaborative agreements.

Arkansas grants APRNs full practice authority after a 4,000-hour collaborative period, so many NPs in the state prescribe GLP-1 receptor agonists independently. PAs require a supervising physician relationship but may prescribe Schedule II through VI medications, and Zepbound is unscheduled.

Obesity medicine specialists are concentrated in Little Rock, Fayetteville, and Jonesboro. But you do not need a specialist referral. Primary care physicians, endocrinologists, and internal medicine providers routinely prescribe tirzepatide. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends tirzepatide as a first-line pharmacotherapy option for patients with a BMI of 30 or greater, or 27 or greater with comorbidities.

If your local provider is unfamiliar with tirzepatide dosing, a telehealth obesity medicine visit can fill the gap without requiring travel.

How Telehealth Prescribing Works in Arkansas

Arkansas permits telehealth prescribing for Zepbound. Good news if you live in a rural county.

The Arkansas Telemedicine Act allows out-of-state providers to treat Arkansas patients as long as the provider holds an Arkansas medical license or a qualifying interstate compact license. For weight management consultations, most telehealth platforms use a synchronous video visit to establish the patient-provider relationship before prescribing.

A typical telehealth Zepbound visit follows this sequence: you complete a health intake form, upload or order qualifying labs, attend a 15- to 30-minute video consultation, and receive an electronic prescription sent directly to a pharmacy. The entire process from sign-up to prescription can happen within 3 to 7 days if labs are already in hand.

Some telehealth platforms partner with 503A compounding pharmacies, which may offer compounded tirzepatide at a lower cost than brand-name Zepbound. Others route prescriptions to retail chains like Walgreens, CVS, or Kroger pharmacies operating within Arkansas. Confirm with your provider which pharmacy network they use before your visit, because switching mid-treatment adds unnecessary delays.

What Labs Are Required Before Starting Zepbound?

Most prescribers require baseline labs before initiating tirzepatide. No Arkansas-specific law mandates a particular lab panel, but clinical practice standards and insurance prior authorization forms typically demand the following:

Standard pre-treatment lab panel:

• Hemoglobin A1c (HbA1c) or fasting glucose
• Comprehensive metabolic panel (CMP), which includes kidney and liver function markers
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Thyroid-stimulating hormone (TSH)

The TSH check matters. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is not a theoretical concern; prescribers screen for it and document the result.

Some providers also order a baseline body composition analysis (DEXA or bioimpedance) to track lean mass preservation during treatment. The American Association of Clinical Endocrinology (AACE) recommends monitoring body composition during GLP-1-based weight loss to detect sarcopenia early.

If you arrive at your telehealth or in-person visit with recent labs (drawn within 90 days), most clinicians will accept them. Labs older than 90 days typically need to be repeated.

Navigating Insurance and Prior Authorization in Arkansas

This is where most patients hit friction. Brand-name Zepbound has a wholesale acquisition cost exceeding $1,000 per month, and nearly every payer requires prior authorization (PA).

Arkansas Medicaid covers Zepbound under a limited PA pathway. "Limited" means Medicaid will consider coverage, but requires documented evidence of BMI qualifying criteria, at least one failed lifestyle modification attempt (typically 3 to 6 months), and the prescriber must be an in-network provider. Approval is not guaranteed, and denial rates for GLP-1 receptor agonists under state Medicaid programs remain high nationally.

Commercial insurance (Blue Cross Blue Shield of Arkansas, QualChoice, Ambetter) varies by plan. BCBS of Arkansas has covered tirzepatide for type 2 diabetes (under the Mounjaro brand) since 2023. Coverage for the obesity indication under the Zepbound label depends on whether the plan includes anti-obesity medication (AOM) benefits. Self-funded employer plans may have different formulary rules than fully insured state-regulated plans.

PA documentation typically requires:

1. Current BMI calculation with height and weight recorded at the visit
2. Diagnosis code (E66.01 for morbid obesity, E66.09 for other obesity, or E66.3 for overweight)
3. Documentation of at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
4. Evidence of lifestyle modification (diet counseling, exercise program) for 3 to 6 months
5. Lab results (A1c, CMP, lipid panel)
6. Prescriber's clinical rationale and treatment plan

PA turnaround times in Arkansas average 5 to 14 business days. If denied, you have the right to a peer-to-peer review, where your prescriber speaks directly with the insurer's medical director. A 2023 analysis published in JAMA Network Open found that only 28% of commercially insured adults with obesity had plan-level coverage for GLP-1 receptor agonists, highlighting systemic access barriers that apply nationwide, including in Arkansas.

503A Compounding Pharmacies in Arkansas

Arkansas licenses 503A compounding pharmacies under the Arkansas State Board of Pharmacy. These pharmacies may compound tirzepatide for individual patients with a valid prescription, provided they follow United States Pharmacopeia (USP) 797 and 800 sterile compounding standards.

Compounded tirzepatide is not FDA-approved Zepbound. It uses the same active molecule but is prepared by the pharmacy rather than manufactured by Eli Lilly. The FDA has stated that compounding of tirzepatide is permitted while the drug remains on the shortage list, but the agency continues to update that status.

Pricing for compounded tirzepatide from Arkansas-based 503A pharmacies typically ranges from $300 to $550 per month, significantly less than brand-name Zepbound. Some telehealth platforms include pharmacy fulfillment in their monthly subscription fees.

Before using a compounding pharmacy, verify three things: that the pharmacy holds a current Arkansas Board of Pharmacy license, that it follows USP 797 standards for sterile compounding, and that your prescriber is comfortable writing for compounded product. Not all providers will.

Zepbound Dosing and What to Expect in the First 12 Weeks

Tirzepatide follows a fixed dose-escalation schedule per the FDA-approved prescribing information:

• Weeks 1 through 4: 2.5 mg subcutaneously once weekly (initiation dose, not a therapeutic dose)
• Week 5 onward: 5 mg once weekly
• Dose increases: In 2.5 mg increments every 4 weeks as tolerated, up to a maximum of 15 mg weekly

The 2.5 mg starting dose is designed to minimize gastrointestinal side effects. Nausea, the most commonly reported adverse event, affected 24% of participants in the SURMOUNT-1 trial at the 15 mg dose, though most episodes were mild to moderate and peaked during dose escalation [1]. Constipation occurred in 11.7% and diarrhea in 9.4% of participants on the 15 mg arm.

Most Arkansas prescribers schedule a follow-up visit (telehealth or in-person) at week 4 to assess tolerability before stepping up to 5 mg. Weight loss in the first 4 weeks on the 2.5 mg dose is typically modest, averaging 3 to 5 pounds. Meaningful weight reduction accelerates between weeks 8 and 20 as the dose reaches therapeutic levels.

Patients should inject in the abdomen, thigh, or upper arm, rotating injection sites weekly. Zepbound comes in a single-dose pen that requires no reconstitution. Compounded tirzepatide may arrive as a multi-dose vial requiring syringe draw, depending on the pharmacy.

Transferring a Zepbound Prescription to Arkansas

If you are moving to Arkansas or splitting time between states, you can transfer an existing Zepbound prescription. Arkansas accepts prescription transfers from any U.S. state for non-controlled medications. Since tirzepatide is unscheduled, the transfer is straightforward.

Your current pharmacy can initiate a transfer to any Arkansas pharmacy by calling or sending an electronic transfer request. Alternatively, your prescriber can send a new prescription directly to an Arkansas pharmacy.

One caveat: if your out-of-state prescription was for compounded tirzepatide from a 503B outsourcing facility, the receiving Arkansas pharmacy must also be licensed to compound sterile injectables. Retail chains like CVS or Walgreens will only fill brand-name Zepbound. Confirm pharmacy capabilities before requesting the transfer.

Insurance coverage may also change. If your prior plan was out-of-state, switching to an Arkansas-based plan may require a new prior authorization under the new insurer's formulary.

Arkansas-Specific Considerations for Long-Term Treatment

Long-term adherence to tirzepatide requires ongoing prescriber visits (typically every 3 to 6 months), periodic lab monitoring, and consistent pharmacy access. Arkansas patients in rural counties may find telehealth follow-ups more practical than in-person visits.

The SURMOUNT-1 trial ran for 72 weeks, and participants who discontinued tirzepatide regained approximately two-thirds of their lost weight within one year, according to the SURMOUNT-4 extension study published in JAMA (2024). This finding reinforces that tirzepatide is a long-term therapy, not a short course. Plan your access, insurance, and pharmacy logistics accordingly.

Arkansas's Prescription Drug Monitoring Program (PDMP) does not track tirzepatide since it is unscheduled. There are no state-level quantity limits or refill restrictions beyond what your insurer imposes.

For patients paying out of pocket, Eli Lilly's Zepbound savings card may reduce costs to as low as $25 per month for commercially insured patients who meet eligibility criteria. The savings card does not apply to government insurance (Medicaid, Medicare, Tricare). Check Lilly's patient support page for current terms.